Hemogenic Reprogramming of Human Fibroblasts by Enforced Expression of Transcription Factors
November 4th, 2019
7.6K views
This protocol demonstrates the induction of a hemogenic program in human dermal fibroblasts by enforced expression of the transcription factors GATA2, GFI1B and FOS to generate hematopoietic stem and progenitor cells.
Overview
This protocol demonstrates the induction of a hemogenic program in human dermal fibroblasts by enforced expression of the transcription factors GATA2, GFI1B, and FOS to generate hematopoietic stem and progenitor cells. This method provides a tractable in vitro platform for studying human hematopoietic development through direct cell reprogramming.
Key Study Components
Area of Science
- Cell Reprogramming
- Hematopoietic Development
- Stem Cell Biology
Background
- Human hematopoietic development is challenging to study in vivo.
- Direct reprogramming of fibroblasts offers a novel approach.
- Transcription factors play a crucial role in cell fate determination.
- This study aims to generate patient-specific hematopoietic stem cells.
Purpose of Study
- To generate hematopoietic stem and progenitor cells from fibroblasts.
- To provide a detailed protocol for the reprogramming process.
- To facilitate future studies in stem cell transplantation.
Methods Used
- Transduction of human dermal fibroblasts with lentiviral vectors.
- Use of transcription factors GATA2, GFI1B, and FOS.
- Cell culture techniques for optimal growth conditions.
- Collection and concentration of lentiviral supernatants.
Main Results
- Successful conversion of fibroblasts into hemogenic precursors.
- Establishment of a reliable protocol for generating hematopoietic cells.
- Demonstration of the efficiency of the transduction process.
- Potential for generating sufficient cell numbers for transplantation.
Conclusions
- The protocol provides a valuable tool for studying hematopoietic development.
- Direct reprogramming of fibroblasts is a promising approach.
- Future applications may enhance stem cell therapies.
Frequently Asked Questions
What are the key transcription factors used in this study?
The key transcription factors are GATA2, GFI1B, and FOS.
How does this method benefit stem cell research?
It provides a simple in vitro platform for generating hematopoietic cells.
What type of cells are being reprogrammed?
Human dermal fibroblasts are being reprogrammed into hematopoietic stem and progenitor cells.
What is the significance of generating patient-specific cells?
Patient-specific cells can improve the efficacy of stem cell transplantation.
What are the incubation conditions for HEK293T cells?
HEK293T cells are incubated at 37 degrees Celsius with 5% carbon dioxide.
How long should the fibroblasts be incubated after transduction?
Fibroblasts should be incubated for 48 hours after transduction with doxycycline.
Executive Industry Relevance
This protocol enables direct reprogramming of human fibroblasts into hemogenic precursors, providing a tractable in vitro system to model human hematopoietic stem cell emergence. By bypassing pluripotent intermediates, it reduces variability and accelerates mechanistic studies of endothelial-to-hematopoietic transition. The approach supports target validation and assay development for hematopoiesis-focused discovery programs.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of transcriptional regulators like GATA2 during hemogenic fate specification.
- Operational Value: Provides a defined cellular system to assess factor dependency and pathway activity.
Screening & Assay Development
- Scientific Value: Generates reproducible hemogenic intermediates for compound screening and phenotypic readouts.
- Operational Value: Supports scalable production of reprogrammed cells for assay standardization.
Translational & Preclinical Research
- Scientific Value: Produces hematopoietic progeny capable of engrafting immunodeficient mice, enabling functional validation.
- Operational Value: Offers a patient-specific cell source for preclinical efficacy and safety testing.
Pipeline & Workflow Integration
The method fits within early discovery to preclinical workflows by providing a reprogrammed cellular platform that bridges fibroblast input to hematopoietic output.
- Discovery Biology: Supports hypothesis testing of transcription factor combinations in lineage conversion.
- Screening: Enables assay-ready hemogenic cells for evaluating small molecules or genetic perturbations.
- Analytics: Facilitates quantitative measurement of surface markers (CD49f, CD9, CD143) and transcriptional dynamics.
- Translational Research: Connects in vitro reprogramming to in vivo engraftment, supporting risk-adjusted advancement.
- Enterprise Reuse: Establishes a reusable lentiviral transduction system for factor screening and mechanistic dissection.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in modeling human hematopoietic development.
- Operational Value: Standardizes reprogramming via defined transcription factor lentiviruses and doxycycline induction.
- Strategic Value: Reduces reliance on heterogeneous primary samples, improving go/no-go decision consistency.
- Portfolio Impact: Enables risk-aware prioritization of targets involved in hemogenic endothelial transition.
Implementation Considerations
- Requires expertise in lentiviral production, titration, and safe handling in containment facilities.
- Depends on access to transduction-optimized fibroblast cultures and hematopoietic differentiation media.
- Necessitates standardized doxycycline induction protocols across laboratories for reproducibility.
- Involves optimization of viral volume to balance reprogramming efficiency with cell viability.
- Benefits from integration with downstream analytics like flow cytometry and single-cell sequencing.
Biopharma FAQs
Why does GATA2 binding to ITGA6 and ACE matter for target validation?
Chromatin immunoprecipitation sequencing showed GATA2 binding to regulatory regions of ITGA6 and ACE during reprogramming, linking the transcription factor to hemogenic marker expression. This enables mechanistic de-risking by validating direct transcriptional targets in the endothelial-to-hematopoietic transition.
How does isolating the independent variable of transcription factor combination support discovery pipeline progression?
By testing individual factors (GATA2, GFI1B, FOS) or their pool, researchers can isolate the effect of each variable on hemogenic induction. This supports lead identification by clarifying which factors are necessary or sufficient for phenotype initiation.
What quantitative dependent variable measurements enable assessment of reprogramming efficiency?
Flow cytometry measuring CD49f, CD9, and CD143 double-positive cells provides a quantitative readout of hemogenic fate induction, with approximately 17% positivity observed at day 25. These measurements allow comparison across conditions and factor dosages.
Why do replication requirements matter for cross-functional collaboration in this reprogramming model?
Consistent reprogramming efficiency depends on standardized lentiviral titration, fibroblast seeding density, and doxycycline timing across replicates. Reproducibility ensures that discovery, screening, and preclinical teams can rely on comparable hemogenic cell yields.
What statistical analysis capabilities are required before implementing this model in a discovery workflow?
Implementation requires the ability to quantify marker expression via flow cytometry, compare percentages across experimental groups, and assess statistical significance of changes in hemogenic cell frequency. This enables data-driven decisions on factor efficacy and culture condition optimization.
